<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Canagliflozin and metformin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Canagliflozin and metformin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Canagliflozin and metformin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="96755" href="/d/html/96755.html" rel="external">see "Canagliflozin and metformin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F25573727"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Lactic acidosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (&gt;5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate:pyruvate ratio; and metformin plasma levels generally &gt;5 mcg/mL. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (eg, carbonic anhydrase inhibitors such as topiramate), ≥65 years of age, having a radiological study with contrast, surgery and other procedures, hypoxic states (eg, acute heart failure), excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the full prescribing information. If metformin-associated lactic acidosis is suspected, immediately discontinue canagliflozin/metformin and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F25593249"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Invokamet;</li>
<li>Invokamet XR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871790"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Invokamet</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F25573728"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Biguanide;</li>
<li>
                        Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor;</li>
<li>
                        Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F25746086"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Correct volume depletion, if present, prior to initiation. May require a gradual dose reduction of insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinides) to avoid hypoglycemia (AACE/ACE [Garber 2020]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Additional therapeutic considerations may apply; refer to individual agents for information.</p>
<p style="text-indent:-2em;margin-left:4em;">Individualize dose based on patient's current antidiabetic regimen. May gradually increase dose based on effectiveness and tolerability.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients naive to canagliflozin or metformin</i>: <b>Oral: </b>Initial: Canagliflozin 100 mg/metformin 1 g per day in 2 divided doses (immediate release) or once daily (extended release).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients on metformin</i>: <b>Oral: </b>Initial: Canagliflozin 100 mg/day plus similar total daily dose of metformin in 2 divided doses (immediate release) or once daily (extended release). Patients taking an evening dose of metformin extended release should skip their last dose before starting canagliflozin/metformin extended release the following morning.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients on canagliflozin</i>: <b>Oral: </b>Initial: Metformin 1 g/day plus same total daily dose of canagliflozin in 2 divided doses (immediate release) or once daily (extended release).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients switching from combination therapy of canagliflozin and metformin as separate tablets:</i>
<b>Oral: </b>Administer same total daily dose of canagliflozin plus similar total daily dose of metformin in 2 divided doses (immediate release) or once daily (extended release).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients switching from immediate release to extended release</i>: <b>Oral: </b>Use current total daily dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum: <b>Oral: </b>Canagliflozin 300 mg/metformin 2 g per day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990976"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The glycemic efficacy of canagliflozin decreases as kidney function declines.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 45 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Limit the dose of canagliflozin to 100 mg/day. No dosage adjustment is required for metformin.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 30 to &lt;45 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initiation of therapy: </i>Initiation of therapy with canagliflozin/metformin is not recommended. Refer also to individual agents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuation of existing therapy:</i> If eGFR falls between 30 and &lt;45 mL/minute/1.73 m<sup>2</sup> during therapy, consider benefits/risks of continuing therapy. If continued, limit the dose of canagliflozin to 100 mg/day; metformin may be continued at a reduced dose up to a maximum of 500 mg twice daily with close monitoring of kidney function (ADA [Lipska 2011]; Inzucchi 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50988356"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The manufacturer recommends avoiding metformin because liver disease is considered a risk factor for the development of lactic acidosis during metformin therapy. However, continued use of metformin in patients with diabetes and chronic liver disease with impaired hepatic function may be associated with a survival benefit in carefully selected patients; use cautiously in patients at risk for lactic acidosis (eg, renal impairment, alcohol use) (Brackett 2010; Crowley 2017; Zhang 2014). For canagliflozin, no dosage adjustment is necessary in patients with mild or moderate hepatic impairment according to the manufacturer's labeling; use of canagliflozin is not recommended in severe hepatic impairment.</p></div>
<div class="block doe drugH1Div" id="F25746087"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor).</p></div>
<div class="block adr drugH1Div" id="F25872220"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block coi drugH1Div" id="F25573730"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of serious hypersensitivity (eg, anaphylaxis, angioedema) to canagliflozin, metformin, or any component of the formulation; severe renal impairment (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>) or patients on dialysis; acute or chronic metabolic acidosis (including diabetic ketoacidosis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Renal function unknown or end-stage renal disease; unstable and/or insulin-dependent (type I) diabetes mellitus; acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, history of ketoacidosis with or without coma; history of lactic acidosis (regardless of precipitating factors); excessive alcohol intake (acute or chronic); severe hepatic dysfunction or clinical or laboratory evidence of hepatic disease; cardiovascular collapse and disease states associated with hypoxemia including cardiorespiratory insufficiency, which are often associated with hyperlactacidemia; stress conditions (eg, severe infection, trauma, surgery and postoperative recovery phase); severe dehydration or shock; pregnancy; breastfeeding; period of time around administration of iodinated contrast materials.</p></div>
<div class="block war drugH1Div" id="F25746079"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone fracture: An increased incidence of bone fracture has been reported in the CANVAS clinical trial program (composed of the CANVAS and CANVAS-R trials); fractures were observed as early as 12 weeks after treatment initiation in the CANVAS trial (Neal 2017; Watts 2016; manufacturer's labeling). The similarly designed CANVAS-R trial (n=5,812) did not show an increased fracture risk when analyzed separately from the CANVAS trial (n=4,330); reasons for this conflicting data within the CANVAS program are not clear (Zhou 2019). Meta-analyses and pooled analyses (excluding CANVAS trial) have not demonstrated a risk of increased fractures (Ruanpeng 2017; Tang 2016; Watts 2016), and fracture risk was not increased in the CREDENCE trial (Perkovic 2019). Consider patient's risk of fracture prior to initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Genital mycotic infections: Canagliflozin may increase the risk of genital mycotic infections (eg, vulvovaginal mycotic infection, vulvovaginal candidiasis, vulvovaginitis, candida balanitis, balanoposthitis). Patients with a history of these infections or uncircumcised males are at greater risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Canagliflozin may cause hyperkalemia. Predisposing factors for hyperkalemia include renal impairment, higher doses (eg, 300 mg daily), and concomitant use of potassium-sparing diuretics, angiotensin-converting-enzyme [ACE] inhibitors, and angiotensin receptor blockers (ARBs) (Weir 2014). In the CREDENCE trial, use of canagliflozin 100 mg daily in patients with a mean eGFR ~56 ± 18 mL/minute/1.73 m<sup>2</sup> did not increase the risk of hyperkalemia compared to placebo (Perkovic 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions (eg, angioedema, anaphylaxis), some serious, generally occurs within hours to days after therapy initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ketoacidosis: Cases of ketoacidosis (some fatal) have been reported in patients with type 1 and type 2 diabetes mellitus receiving sodium glucose cotransporter-2 (SGLT2) inhibitors, including canagliflozin; in some cases, patients have presented with normal or only modestly elevated blood glucose (&lt;250 mg/dL). Risk may be increased with higher doses. Before initiating treatment, consider risk factors that may predispose to ketoacidosis (eg, pancreatic insulin deficiency, dose decreases of insulin, caloric restriction, alcohol abuse, acute febrile illness, surgery, any other extreme stress event). Consider temporary discontinuation of therapy at least 3 days prior to surgery or any event that may precipitate ketoacidosis; ensure risk factors are resolved prior to reinitiating therapy. Patients presenting with nausea/vomiting, abdominal pain, generalized malaise, and/or shortness of breath should be assessed immediately for ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactic acidosis: Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue use in patients with conditions associated with dehydration, hypoperfusion, sepsis, or hypoxemia. Temporarily discontinue therapy in patients with restricted food and fluid intake. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lower limb amputation: An increased risk of lower limb amputations associated with canagliflozin use was observed in CANVAS (5.9 vs 2.8 events per 1,000 patient-years) and CANVAS-R (7.5 vs 4.2 events per 1,000 patient-years), two large, randomized, placebo-controlled trials evaluating patients with type 2 diabetes who had either established cardiovascular disease or were at risk for cardiovascular disease. Amputations involved the toe, midfoot, or less frequently the leg (above or below the knee). Lower limb infections, gangrene, and diabetic foot ulcers were the most common precipitating factors. Prior to initiation consider risk factors for amputation including prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Counsel patients about the importance of preventative foot care.</p>
<p style="text-indent:-2em;margin-left:4em;">• Necrotizing fasciitis: Cases of necrotizing fasciitis of the perineum (Fournier gangrene), a rare but serious and potentially fatal infection, have been reported in patients receiving canagliflozin. Assess patients presenting with fever or malaise along with genital or perianal pain, tenderness, erythema, or swelling for necrotizing fasciitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal effects: Acute kidney injury has been reported with canagliflozin. Prior to initiation, consider risk factors for acute kidney injury (eg, hypovolemia, chronic renal insufficiency, heart failure, use of concomitant medications [eg, diuretics, ACE inhibitors, angiotensin receptor blockers, or nonsteroidal anti-inflammatory drugs). Temporarily discontinue use with reduced oral intake or fluid losses; discontinue use if acute kidney injury occurs. Additional abnormalities in renal function (decreased eGFR, increased serum creatinine) and adverse effects related to renal function may occur. In the CREDENCE trial, patients with type 2 diabetes and chronic kidney disease (ie, eGFR 30 to 90 mL/minute/1.73 m<sup>2</sup>) and receiving canagliflozin had a greater decline in eGFR at 3 weeks compared to placebo; however, further decline in eGFR tended to be slower with canagliflozin over a median follow-up of 2.6 years (Perkovic 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract infection: Serious urinary infections including urosepsis and pyelonephritis requiring hospitalization have been reported with canagliflozin; treatment increases the risk for urinary tract infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin B<sub>12</sub> concentrations: Long-term metformin use is associated with vitamin B<sub>12</sub> deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Volume depletion: Intravascular volume depletion manifesting as acute transient changes in creatinine or symptomatic hypotension may occur; risk may be increased in patients with renal impairment (ie, eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>), elderly patients, or patients on loop diuretics. Acute kidney injury requiring dialysis and hospitalization has also been reported. Assess volume status prior to initiation in patients at risk of hypotension and correct if depleted.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Use IR tablets after surgery. Absorption may be altered given the anatomic and transit changes created by gastric bypass and sleeve gastrectomy surgery. ER tablets may have a reduced effect after gastric bypass or sleeve gastrectomy due to the direct bypass of the stomach and proximal small bowel with gastric bypass or a more rapid gastric emptying and proximal small bowel transit with sleeve gastrectomy (Mechanick 2020; Melissas 2013). After gastric bypass (Roux-en-Y gastric bypass [RYGB]), administration of IR tablets led to increased absorption (AUC<sub>0-∞</sub> increased by 21%) and bioavailability (increased by 50%) (Padwal 2011). Lactate levels decrease after gastric bypass (RYGB)-induced weight loss irrespective of the use of metformin. Routinely lowering metformin dose after gastric bypass is not necessary as long as normal renal function is preserved (Deden 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">– Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy and closely monitor the patient for the duration of therapy; volume depletion and related adverse events (eg, hypotension, orthostatic hypotension, syncope) have occurred. Fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">– Euglycemic diabetic ketoacidosis: Discontinue therapy 3 to 5 days prior to surgery (Bobart 2016). Postoperatively, assess volume status, caloric intake, and need for diabetes treatment and withhold antidiabetic medication if type 2 diabetes is in remission. Ketoacidosis has been reported in patients with type 1 and type 2 diabetes on SGLT2 inhibitors. In some cases, normal or only modestly elevated blood glucose was present (&lt;250 mg/dL) (van Niekerk 2018). Risk factors include significant reduction in insulin, caloric restriction, stress of surgery, and infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Metformin may be used in patients with stable heart failure (HF); use cautiously or avoid in hypoperfusion (ADA 2023). Risk of lactic acidosis may be increased secondary to hypoperfusion. In a scientific statement from the AHA, metformin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]). Use of metformin in patients with HF may be associated with reduced mortality and reduction in hospital readmission for HF (Crowley 2017; Eurich 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use metformin cautiously in patients at risk for lactic acidosis (Brackett 2010; Crowley 2017; Zhang 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Metformin is substantially excreted by the kidney; the risk of metformin accumulation and lactic acidosis increases with degree of renal impairment. Glycemic efficacy of canagliflozin may be decreased in patients with renal impairment. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution; risk of metformin associated lactic acidosis increases with age. Patients ≥65 years of age may have an increased risk of symptoms related to intravascular volume depletion (eg, hypotension, orthostatic hypotension, postural dizziness, syncope, and dehydration) during canagliflozin therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for use in patients with diabetic ketoacidosis <b>or</b> for glycemic control in patients with type 1 diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients: Use of SGLT2 inhibitors (eg, canagliflozin) is not routinely recommended for glycemic control in hospitalized patients (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Iodinated contrast: Administration of iodinated contrast agents has been associated with post-contrast acute kidney injury; in patients taking metformin, acute decreases in renal function have been associated with an increased risk of lactic acidosis due to reduced metformin excretion (ACR 2021; manufacturer’s labeling). Refer to metformin monograph for additional information.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical procedures: Consider temporary discontinuation of canagliflozin-containing products 3 days prior to surgery; ensure risk factors for ketoacidosis are resolved prior to reinitiating therapy.</p></div>
<div class="block foc drugH1Div" id="F25593250"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invokamet: Canagliflozin 50 mg and metformin hydrochloride 500 mg, Canagliflozin 150 mg and metformin hydrochloride 500 mg, Canagliflozin 50 mg and metformin hydrochloride 1000 mg, Canagliflozin 150 mg and metformin hydrochloride 1000 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invokamet XR: Canagliflozin 50 mg and metformin hydrochloride 500 mg, Canagliflozin 150 mg and metformin hydrochloride 500 mg, Canagliflozin 50 mg and metformin hydrochloride 1000 mg, Canagliflozin 150 mg and metformin hydrochloride 1000 mg</p></div>
<div class="block geq drugH1Div" id="F25593248"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F25745808"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Invokamet XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50-500 mg (per each): $11.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50-1000 mg (per each): $11.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-500 mg (per each): $11.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-1000 mg (per each): $11.97</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Invokamet Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50-500 mg (per each): $11.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50-1000 mg (per each): $11.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-500 mg (per each): $11.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-1000 mg (per each): $11.97</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871791"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invokamet: Canagliflozin 50 mg and metformin hydrochloride 500 mg, Canagliflozin 50 mg and metformin hydrochloride 850 mg [DSC], Canagliflozin 150 mg and metformin hydrochloride 500 mg, Canagliflozin 150 mg and metformin hydrochloride 850 mg [DSC], Canagliflozin 50 mg and metformin hydrochloride 1000 mg, Canagliflozin 150 mg and metformin hydrochloride 1000 mg</p></div>
<div class="block adm drugH1Div" id="F25746092"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Administer twice daily with meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Administer once daily with morning meal. Swallow tablets whole; do not crush, cut, or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Tablet: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Consider switching to separate IR components. Antidiabetic medications may be held in the immediate postoperative period due to endocrine and gut hormone shifts induced by surgery, low carbohydrate postoperative diet, and effects of some medications on diuresis (sodium-glucose co-transporter-2 inhibitors).</p></div>
<div class="block meg drugH1Div" id="F25746070"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Invokamet, Invokamet XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F204353s042%2C205879s019lbl.pdf%23page%3D56&amp;token=cUF4GEWBaE4GSrpvnevFERwIAaY96tQPZuSzYuEKuwblMSqArNF9EMdTOkwBhJBqabdw2ViZgZx9N2Q2nkYrG6vItxDdGxQNi7hQ8Ww4KtXfdgedjlo5JZ3vh9FOHB7B&amp;TOPIC_ID=96545" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204353s042,205879s019lbl.pdf#page=56</a></p></div>
<div class="block use drugH1Div" id="F25573725"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diabetes mellitus, type 2, treatment:</b> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p></div>
<div class="block mst drugH1Div" id="F25707879"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MetFORMIN may be confused with metroNIDAZOLE</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to increased risk of urogenital infections, especially in women during the first month of use. In addition, a higher risk of euglycemic diabetic ketoacidosis has been observed in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F25590551"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F25590548"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of MetFORMIN. Specifically, excessive alcohol ingestion (acute or chronic) may potentiate the risk of lactic acidosis.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalexin: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (including lactic acidosis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Canagliflozin may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to this combination or use of lower metformin doses. Carefully weigh the risk of metformin toxicities (including lactic acidosis) against the benefit of combining dolutegravir with metformin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Consider alternatives to this combination when possible. If combined, monitor for increased effects/toxicities of OCT2 substrates and consider OCT2 substrate dose reductions when appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with MATE1/2-K substrates when possible. If combined, monitor for increased MATE1/2-K substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with OCT2 substrates when possible. If combined, monitor for increased OCT2 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fludeoxyglucose F 18: MetFORMIN may diminish the diagnostic effect of Fludeoxyglucose F 18.  Management: Consider holding metformin for 48 hours or longer prior to PET scans using fludeoxyglucose F18 (FDG-F18) when imaging of the colon or intestine is required. Consider increased monitoring of blood glucose when metformin is held.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foslevodopa: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Systemic): May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guar Gum (Partially Hydrolyzed): May decrease the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may enhance the hypoglycemic effect of Insulins.  Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Canagliflozin may enhance the hypotensive effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MATE1/2-K Inhibitors: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylol Cephalexin: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Canagliflozin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, and Ritonavir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Patiromer: May decrease the serum concentration of MetFORMIN. Management: Administer metformin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May increase the serum concentration of MetFORMIN. Management: Limit the metformin dose to a maximum of 1,700 mg per day when used together with ranolazine 1,000 mg twice daily. Monitor patients for metformin toxicities, including lactic acidosis and carefully weigh the risks and benefits of this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risdiplam: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of risdiplam with MATE substrates if possible. If the combination cannot be avoided, monitor closely for adverse effects. Consider a reduced dose of the MATE substrate according to that substrate's labeling if appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of MATE substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the MATE substrate and consider a reduced dose of the MATE substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of OCT2 substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the OCT2 substrate and consider a reduced dose of the OCT2 substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased. MetFORMIN may increase the serum concentration of Topiramate. Topiramate may increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: May diminish the therapeutic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): MetFORMIN may diminish the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56016461"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Metformin may increase ovulation in premenopausal anovulatory patients resulting in unintended pregnancies.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block pri drugH1Div" id="F25746076"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Metformin crosses the placenta (ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">The manufacturer recommends that alternative therapies be used in pregnant patients during the second and third trimesters.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for information related to the treatment of diabetes mellitus in pregnancy.</p></div>
<div class="block brc drugH1Div" id="F25746078"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Metformin is present in breast milk; excretion of canagliflozin is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, breastfeeding is not recommended by the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block dic drugH1Div" id="F25746091"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy based on American Diabetes Association recommendations is an integral part of therapy.</p></div>
<div class="block mop drugH1Div" id="F25746094"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Plasma glucose (individualize frequency based on treatment regimen, hypoglycemia risk, and other patient-specific factors) (ADA 2023). Monitor renal function (eGFR) prior to therapy initiation and at least annually or at least every 3 to 6 months if eGFR is &lt;60 mL/minute/1.73 m<sup>2</sup> (KDIGO 2020). Monitor hematologic parameters (eg, hemoglobin/hematocrit, red blood cell indices) annually; folate if megaloblastic anemia is suspected; volume status (eg, BP, hematocrit, electrolytes); serum potassium (periodically after initiation in renal impairment and those predisposed to hyperkalemia); signs/symptoms of genital mycotic infections and urinary tract infection; signs/symptoms of heart failure; lower limb and feet (sores, ulcers, infection). If signs/symptoms of ketoacidosis (eg, nausea/vomiting, abdominal pain, malaise, shortness of breath), confirm diagnosis by direct measurement of blood ketones and arterial pH (measurement of serum bicarbonate or urinary ketones may not be adequate) (AACE [Handelsman 2016]). Monitor vitamin B<sub>12</sub> serum concentrations every 1 to 2 years, particularly in patients who have been treated with metformin for ≥4 years, or in patients with peripheral neuropathy, anemia, or risk factors for vitamin B<sub>12</sub> deficiency (eg, malabsorption syndromes, reduced dietary intake) (ADA 2023; KDIGO 2020; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>HbA<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F25746083"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults (AACE [Samson 2023]; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note</b>
<b>: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note: </b>Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F25746081"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Canagliflozin: By inhibiting sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, canagliflozin reduces reabsorption of filtered glucose from the tubular lumen and lowers the renal threshold for glucose (RTG). SGLT2 is the main site of filtered glucose reabsorption; reduction of filtered glucose reabsorption and lowering of RTG result in increased urinary excretion of glucose, thereby reducing plasma glucose concentrations. </p>
<p style="text-indent:0em;margin-top:2em;">Metformin: Decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization).</p></div>
<div class="block phk drugH1Div" id="F25746084"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Refer to individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F25576794"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Invokana duo | Vokanamet</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Invokamet | Invokamet xr</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Vokanamet</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. https://www.acr.org/Clinical-Resources/Contrast-Manual. Published January 2021. Accessed July 13, 2021.</div>
</li>
<li>
<div class="reference">
                  American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27699391">
<a name="27699391"></a>Bobart SA, Gleason B, Martinez N, Norris K, Williams SF. Euglycemic ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors: a case report. <i>Ann Intern Med</i>. 2016;165(7):530-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/27699391/pubmed" id="27699391" target="_blank">27699391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20452916">
<a name="20452916"></a>Brackett CC. Clarifying metformin’s role and risks in liver dysfunction. <i>J Am Pharm Assoc (2003)</i>. 2010;50(3):407-410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/20452916/pubmed" id="20452916" target="_blank">20452916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15932841">
<a name="15932841"></a>Briggs GG, Ambrose PJ, Nageotte MP, et al. Excretion of metformin into breast milk and the effect on nursing infants. <i>Obstet Gynecol</i>. 2005;105:1437-1441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/15932841/pubmed" id="15932841" target="_blank">15932841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28055049">
<a name="28055049"></a>Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. <i>Ann Intern Med</i>. 2017;166(3):191-200. doi:10.7326/M16-1901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/28055049/pubmed" id="28055049" target="_blank">28055049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29058235">
<a name="29058235"></a>Deden LN, Aarts EO, Aelfers SCW, et al. Risk of metformin-associated lactic acidosis (MALA) in patients after gastric bypass surgery. <i>Obes Surg</i>. 2018;28(4):1080-1085. doi:10.1007/s11695-017-2974-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/29058235/pubmed" id="29058235" target="_blank">29058235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23508758">
<a name="23508758"></a>Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. <i>Circ Heart Fail</i>. 2013;6(3):395-402. doi:10.1161/CIRCHEARTFAILURE.112.000162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/23508758/pubmed" id="23508758" target="_blank">23508758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118196">
<a name="20118196"></a>Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. <i>Drug Metab Dispos</i>. 2010;38:833-840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/20118196/pubmed" id="20118196" target="_blank">20118196</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Food and Drug Administration website. <a href="http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm</a>. Published December 4, 2015. Accessed October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12545145">
<a name="12545145"></a>Gardiner SJ, Kirkpatrick CM, Begg EJ, et al. Transfer of metformin into human milk. <i>Clin Pharmacol Ther</i>. 2003;73:71-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/12545145/pubmed" id="12545145" target="_blank">12545145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12436333">
<a name="12436333"></a>Hale TW, Kristensen JH, Hackett LP, et al. Transfer of metformin into human milk. <i>Diabetologia</i>. 2002;45:1509-1514.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/12436333/pubmed" id="12436333" target="_blank">12436333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27082665">
<a name="27082665"></a>Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. <i>Endocr Pract</i>. 2016;22(6):753-762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/27082665/pubmed" id="27082665" target="_blank">27082665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Invokamet.1">
<a name="Invokamet.1"></a>Invokamet (canagliflozin and metformin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Invokamet.2">
<a name="Invokamet.2"></a>Invokamet (canagliflozin and metformin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Invokamet.3">
<a name="Invokamet.3"></a>Invokamet XR (canagliflozin and metformin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2023.</div>
</li>
<li>
<div class="reference">
                  Invokana (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25536258">
<a name="25536258"></a>Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. <i>JAMA</i>. 2014;312(24):2668-2675. doi:10.1001/jama.2014.15298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/25536258/pubmed" id="25536258" target="_blank">25536258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21617112">
<a name="21617112"></a>Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. <i>Diabetes Care</i>. 2011;34(6):1431-1437. doi:10.2337/dc10-2361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/21617112/pubmed" id="21617112" target="_blank">21617112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160151">
<a name="23160151"></a>Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. <i>Ann Surg</i>. 2013;258(6):976-982. doi:10.1097/SLA.0b013e3182774522<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/23160151/pubmed" id="23160151" target="_blank">23160151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29166232">
<a name="29166232"></a>Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <i>N Engl J Med.</i> 2017;377(21):2099. doi:10.1056/NEJMc1712572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/29166232/pubmed" id="29166232" target="_blank">29166232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21478461">
<a name="21478461"></a>Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. <i>Diabetes Care</i>. 2011;34(6):1295-1300. doi:10.2337/dc10-2140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/21478461/pubmed" id="21478461" target="_blank">21478461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular and Stroke Nursing, Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30990260">
<a name="30990260"></a>Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. <i>N Engl J Med</i>. 2019;380(24):2295-2306. doi:10.1056/NEJMoa1811744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/30990260/pubmed" id="30990260" target="_blank">30990260</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Perkovic V, Badve SV, Bakris GL. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440590">
<a name="28440590"></a>Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. <i>Diabetes Metab Res Rev</i>. 2017;33(6). doi:10.1002/dmrr.2903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/28440590/pubmed" id="28440590" target="_blank">28440590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27407013">
<a name="27407013"></a>Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. <i>Diabetes Obes Metab</i>. 2016;18(12):1199-1206. doi:10.1111/dom.12742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/27407013/pubmed" id="27407013" target="_blank">27407013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30131409">
<a name="30131409"></a>van Niekerk C, Wallace J, Takata M, Yu R. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin [published online August 20, 2018]. <i>BMJ Case Rep</i>. doi:10.1136/bcr-2017-221527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/30131409/pubmed" id="30131409" target="_blank">30131409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26580237">
<a name="26580237"></a>Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. <i>J Clin Endocrinol Metab</i>. 2016;101(1):157-166. doi:10.1210/jc.2015-3167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/26580237/pubmed" id="26580237" target="_blank">26580237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24786834">
<a name="24786834"></a>Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).<i> Curr Med Res Opin.</i> 2014;30(9):1759-1768. doi:10.1185/03007995.2014.919907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/24786834/pubmed" id="24786834" target="_blank">24786834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24798175">
<a name="24798175"></a>Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. <i>Hepatology</i>. 2014;60(6):2008-2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/24798175/pubmed" id="24798175" target="_blank">24798175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31399845">
<a name="31399845"></a>Zhou Z, Jardine M, Perkovic V, et al. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. <i>Diabetologia</i>. 2019;62(10):1854-1867. doi:10.1007/s00125-019-4955-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/31399845/pubmed" id="31399845" target="_blank">31399845</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 96545 Version 236.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
